161 related articles for article (PubMed ID: 8899851)
1. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats.
Yamazaki M; Akiyama S; Nishigaki R; Sugiyama Y
Pharm Res; 1996 Oct; 13(10):1559-64. PubMed ID: 8899851
[TBL] [Abstract][Full Text] [Related]
2. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system.
Yamazaki M; Tokui T; Ishigami M; Sugiyama Y
Biopharm Drug Dispos; 1996 Dec; 17(9):775-89. PubMed ID: 8968530
[TBL] [Abstract][Full Text] [Related]
3. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.
Yamazaki M; Suzuki H; Hanano M; Tokui T; Komai T; Sugiyama Y
Am J Physiol; 1993 Jan; 264(1 Pt 1):G36-44. PubMed ID: 8430803
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes.
Ishigami M; Tokui T; Komai T; Tsukahara K; Yamazaki M; Sugiyama Y
Pharm Res; 1995 Nov; 12(11):1741-5. PubMed ID: 8592680
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans.
Watanabe T; Kusuhara H; Maeda K; Kanamaru H; Saito Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2010 Feb; 38(2):215-22. PubMed ID: 19875501
[TBL] [Abstract][Full Text] [Related]
6. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
Badolo L; Bundgaard C; Garmer M; Jensen B
Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin.
Hatanaka T; Honda S; Sasaki S; Katayama K; Koizumi T
J Pharmacokinet Biopharm; 1998 Jun; 26(3):329-47. PubMed ID: 10098103
[TBL] [Abstract][Full Text] [Related]
8. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.
Nakai D; Nakagomi R; Furuta Y; Tokui T; Abe T; Ikeda T; Nishimura K
J Pharmacol Exp Ther; 2001 Jun; 297(3):861-7. PubMed ID: 11356905
[TBL] [Abstract][Full Text] [Related]
9. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats.
Yamazaki M; Kobayashi K; Sugiyama Y
Biopharm Drug Dispos; 1996 Oct; 17(7):607-21. PubMed ID: 8894118
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
11. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats.
Yamazaki M; Kobayashi K; Sugiyama Y
Biopharm Drug Dispos; 1996 Nov; 17(8):645-59. PubMed ID: 8950045
[TBL] [Abstract][Full Text] [Related]
12. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.
Tokui T; Nakai D; Nakagomi R; Yawo H; Abe T; Sugiyama Y
Pharm Res; 1999 Jun; 16(6):904-8. PubMed ID: 10397612
[TBL] [Abstract][Full Text] [Related]
13. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
Yamazaki M; Akiyama S; Ni'inuma K; Nishigaki R; Sugiyama Y
Drug Metab Dispos; 1997 Oct; 25(10):1123-9. PubMed ID: 9321514
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.
Watanabe T; Kusuhara H; Maeda K; Shitara Y; Sugiyama Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):652-62. PubMed ID: 19001154
[TBL] [Abstract][Full Text] [Related]
15. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.
Nezasa K; Higaki K; Matsumura T; Inazawa K; Hasegawa H; Nakano M; Koike M
Drug Metab Dispos; 2002 Nov; 30(11):1158-63. PubMed ID: 12386119
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling.
Mao J; Doshi U; Wright M; Hop CECA; Li AP; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):251-258. PubMed ID: 29388346
[TBL] [Abstract][Full Text] [Related]
17. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist.
Imawaka H; Sugiyama Y
J Pharmacol Exp Ther; 1998 Mar; 284(3):949-57. PubMed ID: 9495854
[TBL] [Abstract][Full Text] [Related]
18. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
Johnston TP; Palmer WK
Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
[TBL] [Abstract][Full Text] [Related]
19. Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier.
Kikuchi R; Kusuhara H; Abe T; Endou H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Dec; 311(3):1147-53. PubMed ID: 15292460
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.
Hatanaka T
Clin Pharmacokinet; 2000 Dec; 39(6):397-412. PubMed ID: 11192473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
